NICE Guidance – Service delivery for patients with Sarcomas

Slides:



Advertisements
Similar presentations
Pathway Planning – a model for study initiation or troubleshooting.
Advertisements

March 2002 Outcomes in thyroid cancer: what factors are important? Information Projects Team Outcomes in thyroid cancer: what factors are important? NYCRIS.
John Cape Elizabeth Hancock Colleen Roach Miranda Heneghan Lucy Palmer Lorna Farquharson.
Children and Young People Improving Outcomes Guidance  Key aims of guidance and age specific requirements  Designation of Principal Treatment Centres.
Guidance on Cancer Services Improving Outcomes for People with Skin Tumours including Melanoma NICE Stateholder Consultation version July 2005.
Documented history-Bladder Our Site:
South West Specialised Commissioning Group Selena Blake - Programme Manager Teenage and Young Adults Cancer Services South West Specialised Commissioning.
Work Package 5 Information on centres of expertise for rare cancers WP leader: Sabine Siesling.
SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.
Cancer Outcomes and Services Dataset Linda Wintersgill Information & Audit Manager, NECN.
Improving Outcomes for Children & Young People with Cancer Louise Hooker National Cancer Action Team Cancer Action Team Cancer.
Specialist Breast Units – Does it improve Breast Cancer care? These Power Point presentations are free to download only for academic purposes, with due.
UK Clinical Sarcoma Research. Changes in UK Appointment of Cancer Tsar Use of NICE to evaluate care pathways and technology/drugs Minimum datasets established.
Implementing NICE guidance on autism – developing a local autism team January 2014 Autism: the management and support of children and young people on the.
Gynaecological Oncology Patient Pathway Cecile Bergzoll Gynaecological Oncologist Wellington.
Peer Review for Paediatric Diabetes Ruth Bridgeman.
Tania von Hospenthal – Clinical Services Manager British Association of Dermatologists.
Responsibilities of Sponsor, Investigator and Monitor
Dementia NICE quality standard August What this presentation covers Background to quality standards Publication partners Dementia quality standard.
28 Day Faster Diagnosis Standard
National Clinical Pathway for suspected and confirmed lung cancer:
For Official Use Only-I1-A1
Challenges of Rare Cancers…
Responsibilities of Sponsor, Investigator and Monitor
Oesophago–Gastric Cancer
Delivery of systemic therapy in Gloucestershire for NSCLC
The National Sarcoma Survey 2015
National Oesophago–Gastric Cancer Audit 2015.
Developing a Comprehensive Site Selection Process for a Cancer Network in a Resource-Limited Settings in Sub-Saharan Africa Meg Wirth AMC Operations &
Learning Together local champions workshop October 11th 2017
Coordination (benign lesions)
Paediatric Orthopaedic MSK Pathways Pamela Holland
Jane E Scullion Respiratory Nurse Consultant
Discordance of histo-pathological diagnosis of patients with soft tissue sarcoma referred to tertiary care center. Rastogi,S., Aggarwal, A., Soti, K.,
Oesophago–Gastric Cancer
INTU (NIV) Pre-emptive community and in education regarding NIV
CRUK working group MDT effectiveness proposal
Huron Perth EMS Stroke Update
Multi-Disciplinary Team Meeting Reforms
Pathway for patients with suspected Breast Cancer
Integrated Service Delivery Across the Whole Patient Pathway
Respiratory MCNs - Interstitial lung diseases
Before and After: Patient Cases in Onychomycosis
Survivorship Pathway Template
Management of Vulval Melanoma
Pathway for patients with suspected Upper GI (OG) Cancer
Metastatic Spinal Cord Compression Project
Tit Albreht | Brussels | 7 November 2017
The BAHNO Head & Neck Cancer Surveillance Audit 2018
Making MDTs better Steve Falk
Chemotherapy Services in England: Ensuring quality and safety
‘Improving Outcomes for people with skin tumours, including Melanoma’
Pathway for patients with suspected colorectal cancer
National Oesophago-Gastric Cancer Audit 2018 Annual Report: Slide set
Multi-Disciplinary Team Meeting Reforms
Principal recommendations
The BAHNO Head & Neck Cancer Surveillance Audit 2018
Multi-Disciplinary Team Meeting Reforms
Regional Melanoma & Complex Skin Cancer Meeting
Children and Young People’s Health Support Group National Steering Group for Specialist Children’s Services in Scotland General Surgery for Children.
GTAB/MTB working and terms of reference
Pathway for patients with suspected HPB Cancer Inter Provider Transfer
Impact of 2019 Sarcoma Service specification for Bristol
Multi-Disciplinary Team Meeting Reforms
Multi-Disciplinary Team Meeting Reforms
Early and locally advanced breast cancer
Pathway for patients with suspected Breast Cancer
Breast Multidisciplinary Team Meetings
Multidisciplinary Team Meeting Breast Care
Calderdale and Huddersfield NHS Foundation Trust
Presentation transcript:

NICE Guidance – Service delivery for patients with Sarcomas What are the key points? National Institute of Clinical Excellence

What is NICE? How will the guidance work NICE is a government body that determines the scientific and economic case for adopting a new therapy (it’s called rationing) It is also involved in preparation and dissemination of guidelines Service delivery is peer-reviewed so standards will generally be adhered to

Background – current sarcoma care in UK Late diagnosis (average size =10cm) Uncertainty where to send patients Lot of centres treating few patients Variable adherence to protocols Variable treatment quality

Patients want to be more involved… Identifiable keyworker More information Pre- referral (who they will see, tests, times etc) At referral – written information to take away Post referral – to be able to mull over things

Diagnostic pathway Streamlined Diagnostic centres – managed by networks in conjunction with comprehensive treatment centres - lot of options available All biopsies seen by experienced pathologist Early radiology review for ‘suspicious’ bones

Pathology Ideally no pathologist in isolation Quality approved (system already in place) Formal links with others Training needs National tissue resource

Multidisciplinary Team (MDT) All sarcoma patients must be managed by a MDT Minimum workload 100 new STS / yr, 50 new primary bone (or 100 bone) Why ? Critical mass needed for experience

Core members 2 of everything (Surg/path/radiol/oncol) Keyworker MDT co-ordinator + secretary

Extended members Paediatric Oncology Plastics / Chest / GI / ENT Physiotherapy Palliative care

Process Meet weekly Discuss and document all new cases Diagnostic + treatment facilities Data / Trials / Audit (national) /Information etc

Who can give CT + RT? Nominated units Participate in trials Age related facilities Experience with sarcomas

Rehab + Follow up Involve patients Keyworker responsible for liasing

Audit etc National audit (? Amp rate, LR rate etc) Minimum data set mandatory Research incl tissue storage essential Training for all needed

Advantages Clear patient pathway Treated by experienced MDT Data collection and audit Research Better outcomes?

Summary Rapid referral to diagnostic centre and on to treatment centre Treatment centres agree and adhere to protocols, trials etc Less people treat more patients ? Improved outcomes !